ACTICCA-1

Posted 1 year ago


Notice: Trying to get property 'description' of non-object in /home/www_wgp/wp-content/themes/WGP/acadp/listing/acadp-public-listing-display.php on line 47

ACTICCA-1: A trial of chemotherapy after surgery for cancer of the bile duct or gallbladder

This trial is for people whose cancer has been removed or is due to be removed with an operation. It is open to people whose cancer hasn’t spread to another part of the body.

  • Inclusion Criteria :
    • You have cancer of the bile duct or gallbladder cancer
    • Your cancer has been completely removed by surgery or is due to be completely removed
    • You have surgery within 6 weeks of starting trial chemotherapy
    • You have satisfactory blood test results
    • You are well enough to carry out all your normal activities apart from heavy physical work (performance status 0 or 1)
    • You are willing to use reliable contraception during the trial and for 3 months afterwards if you have chemotherapy and there is any chance that you or your partner could become pregnant
    • You are at least 18 years old
  • Exclusion Criteria :
    • Have already had chemotherapy for biliary tract cancer
    • Have had treatment as part of a clinical trial with an experimental drug or an anti cancer treatment in the last 4 weeks
    • Have problems with your heart such as a heart attack in the last 3 months, angina that isn’t well controlled, an abnormal rhythm of your heart or congestive heart failure
    • Have had had any other cancer in the last 3 years apart from non melanoma skin cancer or carcinoma insitu of the cervix (CIS) that was successfully treated
    • Have an active infection apart from an active hepatitis infection that is being treated
    • Have any other medical condition or mental health problem that the trial team think would affect you taking part in this trial
    • Are pregnant or breastfeeding
  • Study start date : 15/03/2016
  • Study end date : 30/09/2019
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Dr Henning Wege

No post found